Stemgent (Cambridge, MA) a commercial-stage supplier of stemcell related reagents and tools, closed a $5.6M Series B financing. Participants include HealthCare Ventures and Morgenthaler Ventures.

Agile Therapeutics (Princeton, NJ) a clinical-stage pharmaceutical company focused on hormonal contraception, closed a $45M Series B financing. Participants include Investor Growth Capital, Care Capital, ProQuest Investments, Kaiser Permanente Ventures and Novitas Capital.

Inotek Pharmaceuticals (Lexington, MA) a clinical-stage small molecule company focused on age-related macular degeneration, glaucoma, cataract and diabetic retinopathy, closed a $18M Series D financing. Participants include Devon Park Bioventures, Rho Ventures, Care Capital, Pitango Venture Capital, MedImmune Ventures and Bio One Capital.

MedVentive (Waltham, MA) a commercial-stage electronic medical data company, closed a $2.8M Series C, bring the entire financing to $10M. Participants include HLM Venture Partners, Excel Venture Management, Clarian Health Ventures, Core Capital Partners and Long River Ventures.

Bind Biosciences (Cambridge, MA) a preclinical-stage nanoparticle platform company focused on increased efficacy and reduced toxicity of currently marketed drugs, closed a $12.4M Series C financing. Participants include Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension, DHK Investments and Endeavour Vision.

Joule Biotechnologies (Cambridge, MA) a development stage company focused on the conversion of carbon dioxide into ethanol, closed a $30M Series B financing. Participants include Flagship Ventures.

Predictive Biosciences (Lexington, MA) a commercial-stage molecular diagnostic company focused on oncology assays, closed a $25M Series C financing. Participants ProQuest Investments, Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates.

FoldRx Pharmaceuticals (Cambridge) a clinical-stage small molecule company focused on protein misfolding and aggregation in transthyretin amyloid polyneuropathy and other neurodegenerative and cardiovascular diseases, closed a $29M Series C financing. Participants include Novo Ventures, Morgenthaler Ventures, HealthCare Ventures, Fidelity Biosciences, TPG Biotech, Alta Partners and Novartis Venture Funds.

Constellation Pharmaceuticals (Cambridge, MA) a development-stage biopharma focused on epigenetic therapeutic development in the field of oncology, closed a $4.8M Series B financing bringing the total round to $22M. Participants include S.R. One, Altitude Life Science Ventures, Third Rock Ventures, The Column Group and Venrock.

Tetraphase Pharmaceuticals (Watertown, MA) a clinical-stage biopharmaceutical company focused on broad spectrum antibiotics for the treatment of gram negative pathogens, unrinary tract infections and community acquired bacterial pneumonia, closed a $45M Series C financing. Participants include Excel Venture Management, CMEA Capital, Fidelity Biosciences, Flagship Ventures, Mediphase Venture Partners and Skyline Ventures.